Literature DB >> 14688489

Management of older hypertensive patients: is there a difference in approach?

Henry R Black1.   

Abstract

Hypertension is the most common reason Americans visit a physician. Recent analyses from the Framingham Heart Study and others have shown that there will be 70 million hypertensive Americans by the year 2020 and that the overwhelming majority of hypertensives will be 65 years of age or older (what we used to call elderly). The lifetime risk of Americans who live to age 85 years of becoming hypertensive is approximately 90% for both men and women. These individuals, even if they develop an elevated blood pressure late in life, are at significantly increased risk of the many medical complications attributable to hypertension (coronary artery disease, strokes, heart failure, chronic renal disease, and more). Older hypertensives are more likely to have an elevated systolic blood pressure and a low diastolic blood pressure, both of which are related to a loss of article compliance and have an increase in left ventricular mass and a decrease in peripheral resistance. We now have a substantial body of evidence from well done clinical trials that older hypertensives benefit as much or more than younger patients from antihypertensive therapy, so there is no longer any justification for withholding medication from any hypertensive patient whose competing risk or other medical problems are not a contraindication to treatment. These same studies, and practice-based analyses, have shown that the major barrier to reaching blood pressure goal is our failure to reduce systolic blood pressure to <140 mm Hg in most patients and to <130 mm Hg in diabetics and those with renal failure. The basis for all antihypertensive therapy, especially in older people, is thiazide diuretics with either angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, or calcium entry blockers as appropriate add-on treatment. The choice of the second agent depends on other factors, such as comorbidity, lifestyle, and affordability. We must be more aggressive in getting the message out that older hypertensives benefit from treatment and we must overcome the clinical inertia that seems to be a factor in the decision of many physicians not to treat an older patient. No older person should suffer a preventable, life-threatening event or become confined to a wheel chair if attention to lifestyle issues and a few pills a day could avoid that outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688489      PMCID: PMC8099258          DOI: 10.1111/j.1524-6175.2003.02669.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  22 in total

1.  Cardiovascular mortality in hypertensive men according to presence of associated risk factors.

Authors:  F Thomas; A Rudnichi; A M Bacri; K Bean; L Guize; A Benetos
Journal:  Hypertension       Date:  2001-05       Impact factor: 10.190

2.  Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial.

Authors:  M Di Bari; M Pahor; L V Franse; R I Shorr; J Y Wan; L Ferrucci; G W Somes; W B Applegate
Journal:  Am J Epidemiol       Date:  2001-01-01       Impact factor: 4.897

3.  Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III.

Authors:  S S Franklin; M J Jacobs; N D Wong; G J L'Italien; P Lapuerta
Journal:  Hypertension       Date:  2001-03       Impact factor: 10.190

4.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

5.  Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study.

Authors:  S S Franklin; W Gustin; N D Wong; M G Larson; M A Weber; W B Kannel; D Levy
Journal:  Circulation       Date:  1997-07-01       Impact factor: 29.690

6.  Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program.

Authors:  L V Franse; M Pahor; M Di Bari; G W Somes; W C Cushman; W B Applegate
Journal:  Hypertension       Date:  2000-05       Impact factor: 10.190

7.  Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study.

Authors:  Ramachandran S Vasan; Alexa Beiser; Sudha Seshadri; Martin G Larson; William B Kannel; Ralph B D'Agostino; Daniel Levy
Journal:  JAMA       Date:  2002-02-27       Impact factor: 56.272

8.  Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

Authors:  F Forette; M L Seux; J A Staessen; L Thijs; W H Birkenhäger; M R Babarskiene; S Babeanu; A Bossini; B Gil-Extremera; X Girerd; T Laks; E Lilov; V Moisseyev; J Tuomilehto; H Vanhanen; J Webster; Y Yodfat; R Fagard
Journal:  Lancet       Date:  1998-10-24       Impact factor: 79.321

9.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Authors:  Sarah Lewington; Robert Clarke; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

Review 10.  The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview.

Authors:  R S Vasan; D Levy
Journal:  Arch Intern Med       Date:  1996-09-09
View more
  1 in total

1.  Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients.

Authors:  Suzanne Oparil; Steven G Chrysant; Dean Kereiakes; Jianbo Xu; Kathleen J Chavanu; William Waverczak; Robert Dubiel
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-12       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.